The Gift Hidden in Discomfort

Your Saturday VC Breakfast Rundown

Brianna Wiest doesn’t romanticize discomfort, she reframes it. In Uncomfortable Feelings That Actually Indicate You’re on the Right Path, she argues that unease isn’t a signal of failure, but a byproduct of evolution. You only feel resistance when you’re moving against old limits. You only feel fear when you’re standing close to something that matters.

That’s the hidden rhythm of every startup. Founders don’t just build products, they build tolerance for uncertainty. They learn to sit with anxiety without running from it, to listen to doubt without letting it drive. Growth doesn’t feel good. It rarely looks graceful. It’s a thousand moments of friction that eventually turn into traction.

The companies in today’s rundown are living that truth. They’re working through the discomfort, the pivots, the slow quarters, the market noise, because they understand that the pain of refinement is better than the comfort of complacency. Each one of them is learning to stay in the tension long enough for it to turn into insight.

Wiest’s point echoes through every founder who’s still standing after the hard year, the failed pitch, the silent weeks, being uncomfortable isn’t the red flag, it’s the green light. It means you’re stretching into the next version of who you’re supposed to be.

Brook.ai raised $28M in Series B funding (UMass Memorial Health, Morningside) to transform chronic and remote care delivery across the U.S. Oren Nissim and Kit Macgillivray are building an AI-powered platform that merges human support with digital precision, cutting hospital readmissions by 90% and turning continuous care into the new clinical standard.

Temple Digital Group secured $5M in seed funding (Paper Ventures, YZi Capital, CMT Digital) to bring privacy-first institutional trading to blockchain infrastructure. Founded by Evan Varsamis and Dan Simerman, the NYC-based team built a Canton Network–powered exchange where compliance and confidentiality coexist, giving serious institutions a trustworthy bridge into digital asset markets.

BridGene Biosciences closed $28M in Series B+ financing (Bayland Capital, GTJA Investment Group, Proxima Ventures) to accelerate the discovery of small molecule drugs targeting traditionally “undruggable” proteins. Founded by Dr. Ping Cao, the company’s IMTAC platform turns live cells into mapping systems for covalent interactions, driving breakthroughs in oncology and immunology that big pharma can’t ignore.

Assistive Technology Development, Inc. (ATDev) raised $3M in seed funding (Dobrzelecki Legacy Ventures, Uphonest Capital, Life Science Angels) to revolutionize rehabilitation and personal mobility. Todd Roberts and Owen Kent are combining robotics, AI, and empathy through their Reflex exoskeleton, transforming knee rehabilitation into an intelligent at-home experience that restores independence.

Upgrade, Inc. announced $165M in Series G funding (Neuberger Berman, LuminArx Capital Management, DST Global) at a $7.3B valuation to expand its consumer banking and credit products. Renaud Laplanche founded Upgrade to redefine fintech responsibility, serving over seven million customers and proving that transparent lending still scales in a market built on trust.

Peptilogics closed $78M in Series B2 financing (Presight Capital, Thiel Bio, Founders Fund) to advance its engineered peptide therapeutics targeting surgical infections. Founded by Dr. Jonathan Steckbeck, the Pittsburgh-based biotech is using AI and computational design to build precision antibiotics that achieve a 93% infection-free rate, turning infection prevention into an exact science.

ExaCare AI raised $30M in Series A funding (Insight Partners, Foundation Capital, Bienville Capital) to bring automation and intelligence to post-acute operations. Laird Russell and Benjamin Willox are using AI to streamline admissions, referrals, and reimbursement processes across 1,500 facilities, freeing care teams to focus on patients, not paperwork.

HistoSonics, Inc. secured $250M in growth financing (K5 Global, Bezos Expeditions, Wellington Management) to scale its Edison Histotripsy System, the first non-invasive surgical platform that destroys tissue with focused ultrasound. Mike Blue and Josh Stopek are leading the charge toward a surgical future that’s incision-free, heat-free, and globally scalable, ushering in a new era of sound-powered medicine.

Let’s connect and keep the momentum going across the tech ecosystem. Whether you’re a founder shaping the future, a leader driving change, a VC backing bold ideas, or an investor spotting the next big thing—together, we’re pushing boundaries. Proud to be building the future with you.

Let’s connect on LinkedIn and Twitter (X), and keep the conversation going.

Full rundowns live www.devcuration.com

If engineering peace of mind is what you crave, Vention is your zen